Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects

被引：0
|
作者：
Barbara Finck
Helen Tang
Francesca Civoli
Jennifer Hodge
Hillary O’Kelly
Vladimir Vexler
机构：
[1] Coherus BioSciences,
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Biosimilar; Chemotherapy-induced febrile neutropenia; Granulocyte colony-stimulating factors; Pegfilgrastim; Pegfilgrastim-cbqv; Supportive care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：4291 / 4307
页数：16
相关论文
共 50 条
  • [21] A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants
    Tang, Hong
    Civoli, Francesca
    Tatarewicz, Suzanna
    Vandenkoornhuyse, Nathalie
    Finck, Barbara
    ADVANCES IN THERAPY, 2024, 41 (03) : 991 - 1009
  • [22] Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
    Nakov, Roumen
    Gattu, Sreekanth
    Wang, Jessie
    Velinova, Maria
    Schaffar, Gregor
    Skerjanec, Andrej
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (12) : 2790 - 2801
  • [23] Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv
    MacDonald, Karen
    McBride, Ali
    Alrawashdh, Neda
    Abraham, Ivo
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1466 - 1476
  • [24] PROPOSED PEGIFLGRASTIM BIOSIMILAR CHS-1701 DEMONSTRATES PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY TO MARKETED PEGFILGRASTIM IN A RAT NEUTROPENIA MODEL AND IN HEALTHY SUBJECTS
    O'Connor, P.
    Tang, H.
    Civoli, F.
    Finck, B.
    Vexler, V.
    HAEMATOLOGICA, 2017, 102 : 471 - 471
  • [25] Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects.
    Glaspy, John A.
    O'Connor, Paula G.
    Tang, Hong
    Finck, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants
    Hong Tang
    Francesca Civoli
    Suzanna Tatarewicz
    Nathalie Vandenkoornhuyse
    Barbara Finck
    Advances in Therapy, 2024, 41 : 991 - 1009
  • [27] Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
    Ari Brekkan
    Luis Lopez-Lazaro
    Elodie L. Plan
    Joakim Nyberg
    Suresh Kankanwadi
    Mats O. Karlsson
    The AAPS Journal, 21
  • [28] Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
    Brekkan, Ari
    Lopez-Lazaro, Luis
    Plan, Elodie L.
    Nyberg, Joakim
    Kankanwadi, Suresh
    Karlsson, Mats O.
    AAPS JOURNAL, 2019, 21 (05):
  • [29] Pharmacokinetic and pharmacodynamic comparability of B12019: A proposed pegfilgrastim biosimilar
    Roth, K.
    Wessels, H.
    Hoefler, J.
    Jankowsky, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Simulation modeling of cost-savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) and expanded access to biosimilar prophylaxis.
    McBride, Ali
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345